Results showed that T22-PE24-H6 therapeutic nanoparticle, at low concentrations, had an antineoplastic effect in Toledo, SUDHL-6 and U-2932 cells, which express high levels of CXCR4 receptor in their membrane (CXCR4+ DLBCL cell lines). This evidence concerns the gene CXCR4 and diffuse large B-cell lymphoma.